Blue Water Biotech to Participate in the American Urological Association Annual Meeting 2023 to Promote Benign Prostatic Hyperplasia Treatment ENTADFI®

Rhea-AI Summary

Blue Water Biotech announced its participation in the American Urological Association Annual Meeting 2023 from April 28 to May 1 in Chicago. Management, including CEO Joseph Hernandez, will promote ENTADFI®, an FDA-approved treatment for benign prostatic hyperplasia (BPH). They will discuss the upcoming launch strategy and highlight ENTADFI®'s benefits over traditional therapies. Presently, approximately 50% of men over 50 and 90% of those over 85 experience BPH, with 70% facing erectile dysfunction. In 2022, around 44 million prescriptions related to BPH were issued. ENTADFI® is a once-daily oral treatment combining finasteride and tadalafil, aiming to alleviate BPH symptoms with a lower incidence of sexual side effects compared to finasteride alone. The company is transitioning to a commercial-stage biotechnology firm.

CINCINNATI, April 25, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced that Blue Water management will attend the American Urological Association (“AUA”) Annual Meeting 2023 in Chicago, IL from April 28^th to May 1^st, 2023, to promote its asset ENTADFI^®, an FDA-approved treatment for benign prostatic hyperplasia (“BPH”).

Blue Water’s Chief Executive Officer, Joseph Hernandez, and Senior Vice President of Marketing and Business Development, Frank Jaeger, will be in attendance to discuss launch strategy for ENTADFI^® scheduled for later this year, as well as the benefits of ENTADFI^® versus traditional BPH therapies. Hernandez and Jaeger will also be available to discuss the recent rebranding of Blue Water, its transition into a commercial-stage biotechnology company, and the infrastructure being developed to support sales of ENTADFI^®.

“This conference brings together the top urology leaders from around the country, and we are thrilled to attend to promote ENTADFI^®,” said Hernandez. “We believe this product has the potential to transform the BPH landscape and enhance the lives of millions of men that suffer from BPH and associated erectile dysfunction. We encourage all in attendance to visit our booth to connect and learn about ENTADFI^®, as we prepare for launch later this year.”

BPH, a condition in men in which the prostate gland is enlarged but not cancerous, is a common problem that affects the quality of life in approximately half of men over the age of 50 and over 90% of men over the age of 85. Men with BPH suffer from challenges with urination flow, frequency, and urgency, and about 70% of men with BPH also experience sexual dysfunction. In 2022, there were approximately 44 million total prescriptions and 20 million new prescriptions related to BPH symptoms. ENTADFI^® is designed to treat BPH and its associated symptoms. Over 55 million patients in the United States have or are at risk for BPH.

Blue Water management will be available during the conference for one-on-one meetings and can be found at booth 439. Interested parties may request a one-on-one meeting at investors@bluewatervaccines.com or contact Blue Water at (513) 620-4101.

About ENTADFI^®

ENTADFI^® is an oral, once daily treatment for benign prostatic hyperplasia ("BPH") that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, offering a more effective treatment option compared to other available therapies. Clinical trials have shown that ENTADFI^® is more effective in treating BPH symptoms, including urinary frequency, urgency, weak stream, and difficulty initiating or maintaining urination, compared to finasteride monotherapy. Additionally, ENTADFI^® has demonstrated a favorable safety profile, with fewer adverse sexual side effects compared to finasteride. ENTADFI^® reduces potential for adverse sexual side effects, making it a preferred choice for men seeking relief from BPH symptoms without compromising their sexual health. ENTADFI^® has received FDA approval for the indication of initiating treatment of the signs and symptoms of BPH in men with an enlarged prostate for up to 26 weeks. More information about BPH and full ENTADFI^® prescribing information can be found on the product website at https://entadfipatient.com/.

About Blue Water Biotech

Blue Water Biotech, Inc. is a biotechnology company focused on developing transformational therapies to address significant health challenges globally. Headquartered in Cincinnati, OH, the Company holds the rights to proprietary technology developed at the University of Oxford, Cincinnati Children’s Hospital Medical Center, St. Jude Children’s Hospital, and The University of Texas Health Science Center at San Antonio. Blue Water is developing a Streptococcus pneumoniae vaccine candidate, designed to specifically prevent highly infectious middle ear infections, known as acute otitis media (AOM), in children, and prevention of pneumonia in the elderly. The Company is also developing a universal flu vaccine that will provide protection from all virulent strains in addition to licensing a novel norovirus (NoV) S&P nanoparticle versatile virus-like particle (VLP) vaccine platform from Cincinnati Children’s to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, among others. Additionally, the Company is developing a Chlamydia vaccine candidate with UT Health Science Center San Antonio to prevent infection and reduce the need for antibiotic treatment associated with contracting Chlamydia disease. Outside of its vaccine franchise, Blue Water owns ENTADFI®, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. This combination allows men to receive treatment for their symptoms of BPH without the negative sexual side effects typically seen in patients on finasteride alone. For more information about Blue Water, visit www.bluewatervaccines.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Blue Water’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to Blue Water’s ability to realize the benefits of its acquisition of ENTADFI®, risks related to BWV’s ability to expand its business scope and its ability to commercialize ENTADFI®, risks related to the development of Blue Water’s vaccine candidates; the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any vaccine under development, there are significant risks in the development, regulatory approval and commercialization of new products. Blue Water does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Blue Water’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on March 9, 2023 and periodic reports filed with the SEC on or after the date thereof. All of Blue Water’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Media Contact Information:
Blue Water Media Relations
Telephone: (646) 942-5591
Email: Nic.Johnson@russopartnersllc.com

Investor Contact Information:
Blue Water Investor Relations
Email: investors@bluewatervaccines.com

FAQ

What is the purpose of Blue Water Biotech's participation in the AUA Annual Meeting 2023?

Blue Water Biotech is attending to promote its FDA-approved treatment, ENTADFI®, and discuss its launch strategy.

What are the key benefits of ENTADFI® compared to traditional BPH therapies?

ENTADFI® offers a more effective treatment for BPH symptoms with fewer sexual side effects compared to finasteride.

What is the demographic affected by BPH according to Blue Water Biotech's press release?

About 50% of men over 50 and over 90% of men over 85 are affected by benign prostatic hyperplasia (BPH).

What percentage of men with BPH also experience erectile dysfunction?

Approximately 70% of men suffering from BPH also experience erectile dysfunction.

How many prescriptions related to BPH were issued in 2022?

In 2022, there were about 44 million prescriptions related to BPH symptoms.

What is ENTADFI® designed to treat?

ENTADFI® is designed to treat benign prostatic hyperplasia (BPH) and its associated symptoms.

What are the ingredients in ENTADFI®?

ENTADFI® combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor.

Where can interested parties meet Blue Water management at the AUA Annual Meeting?

Blue Water management can be found at booth 439 during the conference.